RZLT

Rezolute, Inc. [RZLT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

RZLT Stock Summary

Top 10 Correlated ETFs

RZLT

Top 10 Correlated Stocks

RZLT

In the News

RZLT Financial details

Company Rating
-
Market Cap
106.99M
Income
-56.85M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
57
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.03
Forward P/E
-
PEG
0.22
P/S
-
P/B
0.56
P/C
-
P/FCF
-0.94
Quick Ratio
13.72
Current Ratio
14.27
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.11
EPS next Y
-
EPS next Q
-
EPS this Y
-52.58%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-3.57%
-
-
-
-
SMA20
-10.06%
SMA50
-44.57%
SMA100
-43.03%
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
-46%
ROC
-0.58%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.72-2.7492
52W High
-
52W Low
-
RSI
69.65
Rel Volume
51.66
Avg Volume
326.82K
Volume
16.89M
Perf Week
60.73%
Perf Month
11.52%
Perf Quarter
-29.48%
Perf Half Y
-18.81%
-
-
-
-
Beta
1.325
-
-
Volatility
0.46%, 0.4%
Prev Close
27.65%
Price
3.97
Change
26.03%

Something similar

Top by Market Cap
APC.DE
META
EMBASSY.NS
VTSAX
ABEA.DE
Top Correlated ETFs
JOYY
LTUR.DE
IQQ5.DE
TUR.PA
TURU.L
Top Correlated Stocks
VRPX
FCEL
EVOK
OXBR
0L35.L
Similar Market Cap
3699.HK
FVAM
0RDB.L
MPV
MDNA.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 326.82K
  • Market Capitalization 106.99M
  • Employee 57
  • CEO Mr. Nevan Charles Elam J.D.
  • Headquarters Redwood City,CA,US
  • IPO Date 2013-01-14
  • Website https://www.rezolutebio.com

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.